Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05683184 · ClinicalTrials.gov registry record · Phase 1
OMAR Opioid Use Disorder
A Phase 1 study of Opioid Use Disorder and Healthy Control, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05683184 is a Phase 1 study of Opioid Use Disorder and Healthy Control that is actively recruiting participants, run by Yale University. The registered enrollment target is 30 participants, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05683184, a Phase 1 study of Opioid Use Disorder and Healthy Control, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this research study is to examine the endocannabinoid (eCB) function in vivo in individuals with opioid use disorder (OUD) by measuring cannabinoid receptor 1 (CB1R) availability.
Conditions Studied
Interventions
- DRUG [11C]OMAR
Study Locations (1)
Connecticut
- Connecticut Mental Health Center, Clinical Neuroscience Research Unit - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-03-10 |
| Est. Completion | 2026-12-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05683184
The ClinicalTrials.gov registry entry for NCT05683184 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (99% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Opioid Use Disorder appearing as the primary indexed condition, and to 1 intervention - of which [11C]OMAR is the first listed.
NCT05683184 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT05683184 about?
NCT05683184 is a clinical study titled "OMAR Opioid Use Disorder". The goal of this research study is to examine the endocannabinoid (eCB) function in vivo in individuals with opioid use disorder (OUD) by measuring cannabinoid receptor 1 (CB1R) availability.
What is the current status of trial NCT05683184?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2023-03-10. Estimated completion is 2026-12-15.
What conditions does trial NCT05683184 study?
This clinical trial studies the following conditions: Opioid Use Disorder, Healthy Control.
What interventions are being tested in trial NCT05683184?
The interventions under investigation include: [11C]OMAR (DRUG).
Who is sponsoring clinical trial NCT05683184?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05683184 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Right Tools, Right Time, Right Place: Telehealth for Opioid Use Disorder in Vulnerable Settings
RECRUITING · Phase 1
-
Study to Assess the Use of Tezampanel for Opioid Withdrawal Syndrome in Treatment-Seeking Patients With Opioid Use Disorder
RECRUITING · Phase 1
-
Cannabis and Opioid Use Disorder
RECRUITING · Phase 1
-
Adjunctive Effects of Psilocybin and a Formulation of Buprenorphine
RECRUITING · Phase 1
-
A Bundled Intervention
RECRUITING · Phase 1
-
Evaluation of the Interactions of Cannabidiol (CBD) With Morphine
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.